(Q43514703)

English

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

author name string

Samuele Calabro

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Elaine Tritto

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Annamaria Pezzotti

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Marianna Taccone

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Alessandro Muzzi

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sylvie Bertholet

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Ennio De Gregorio

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Derek T O'Hagan

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Barbara Baudner

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

0 references

publication date

16 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

3363-3369

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Oil-in-water emulsion adjuvant with influenza vaccine in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

The mechanism of action of MF59 - an innately attractive adjuvant formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Molecular and cellular signatures of human vaccine adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Pathogen recognition and development of particulate vaccines: does size matter?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.007

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.05.007

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43514703&oldid=1990315735"